Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma.
Stolearenco V, Levring TB, Nielsen HM, Lindahl L, Fredholm S, Kongsbak-Wismann M, Willerslev-Olsen A, Buus TB, Nastasi C, Hu T, Gluud M, Côme CRM, Krejsgaard T, Iversen L, Bonefeld CM, Grønbæk K, Met Ö, Woetmann A, Ødum N, Geisler C. Stolearenco V, et al. Among authors: nastasi c. Dermatology. 2021;237(2):283-290. doi: 10.1159/000509159. Epub 2020 Aug 14. Dermatology. 2021. PMID: 32799209
Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.
Bagdonaite I, Wandall HH, Litvinov IV, Nastasi C, Becker JC, Dabelsteen S, Geisler C, Bonefeld CM, Zhang Q, Wasik MA, Zhou Y, Sasseville D, Ødum N, Woetmann A. Bagdonaite I, et al. Among authors: nastasi c. Oncotarget. 2015 Jun 10;6(16):14374-84. doi: 10.18632/oncotarget.3720. Oncotarget. 2015. PMID: 25957418 Free PMC article.
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA, Kopp KL, Litvinov IV, Jønson L, Willerslev-Olsen A, Fredholm S, Petersen DL, Nastasi C, Krejsgaard T, Lindahl LM, Gniadecki R, Mongan NP, Sasseville D, Wasik MA, Iversen L, Bonefeld CM, Geisler C, Woetmann A, Odum N. Sibbesen NA, et al. Among authors: nastasi c. Oncotarget. 2015 Aug 21;6(24):20555-69. doi: 10.18632/oncotarget.4111. Oncotarget. 2015. PMID: 26244872 Free PMC article.
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.
Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Litvinov IV, Fredholm S, Petersen DL, Nastasi C, Gniadecki R, Mongan NP, Sasseville D, Wasik MA, Bonefeld CM, Geisler C, Woetmann A, Iversen L, Kilian M, Koralov SB, Odum N. Willerslev-Olsen A, et al. Among authors: nastasi c. Blood. 2016 Mar 10;127(10):1287-96. doi: 10.1182/blood-2015-08-662353. Epub 2016 Jan 5. Blood. 2016. PMID: 26738536 Free PMC article.
The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma.
Fredholm S, Litvinov IV, Mongan NP, Schiele S, Willerslev-Olsen A, Petersen DL, Krejsgaard T, Sibbesen N, Nastasi C, Bonefeld CM, Persson JL, Straten PT, Andersen MH, Koralov SB, Wasik MM, Geisler C, Sasseville D, Woetmann A, Ødum N. Fredholm S, et al. Among authors: nastasi c. J Invest Dermatol. 2016 Apr;136(4):866-869. doi: 10.1016/j.jid.2015.12.033. Epub 2016 Jan 21. J Invest Dermatol. 2016. PMID: 26802931 Free article. No abstract available.
STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
Lindahl LM, Fredholm S, Joseph C, Nielsen BS, Jønson L, Willerslev-Olsen A, Gluud M, Blümel E, Petersen DL, Sibbesen N, Hu T, Nastasi C, Krejsgaard T, Jæhger D, Persson JL, Mongan N, Wasik MA, Litvinov IV, Sasseville D, Koralov SB, Bonefeld CM, Geisler C, Woetmann A, Ralfkiaer E, Iversen L, Odum N. Lindahl LM, et al. Among authors: nastasi c. Oncotarget. 2016 Jul 19;7(29):45730-45744. doi: 10.18632/oncotarget.10160. Oncotarget. 2016. PMID: 27329723 Free PMC article.
Malignant T cells activate endothelial cells via IL-17 F.
Lauenborg B, Litvinov IV, Zhou Y, Willerslev-Olsen A, Bonefeld CM, Nastasi C, Fredholm S, Lindahl LM, Sasseville D, Geisler C, Wasik MM, Krejsgaard T, Gjerdrum LMR, Iversen L, Odum N, Woetmann A. Lauenborg B, et al. Among authors: nastasi c. Blood Cancer J. 2017 Jul 21;7(7):e586. doi: 10.1038/bcj.2017.64. Blood Cancer J. 2017. PMID: 28731459 Free PMC article. No abstract available.
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.
Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, Klausen U, Donia M, Pedersen LM, Munksgaard L, Ødum N, Woetmann A, Svane IM, Andersen MH. Ahmad SM, et al. Among authors: nastasi c. Oncoimmunology. 2017 Nov 1;7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018. Oncoimmunology. 2017. PMID: 29308318 Free PMC article.
34 results